Value-Based Care in Lung Cancer-Reference-Cited by-同舟云学术

Value-Based Care in Lung Cancer

Published:2016-06-02 Issue:8 Volume:21 Page:903-906
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Eaton Keith D.¹,Jagels Barbara²,Martins Renato G.¹

Affiliation:

1. Department of Medicine, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, USA

2. Seattle Cancer Care Alliance, Seattle, Washington, USA

Abstract

Since the beginning of the 21st century, the treatment of lung cancer has changed dramatically. New treatments are improving survival outcomes for patients but have led to dramatic increases in cost. In a value-based payment system, patients should have access to comprehensive outcome measurements, including survival rates, quality of life, and cost. High value in cancer care will optimize the outcomes that matter to patients relative to cost.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2016-0116

Reference27 articles.

1. Unintended consequences of expensive cancer therapeutics—The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture;Fojo;JAMA Otolaryngol Head Neck Surg,2014

2. Value-based purchasing—National programs to move from volume to value;VanLare;N Engl J Med,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies;Biomedicine & Pharmacotherapy;2024-03

2. Papel de la persona navegadora del paciente en el cáncer de pulmón;Revista del Hospital Italiano de Buenos Aires;2023-09-29

3. Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients;Healthcare;2023-01-18

4. May value-based healthcare practices contribute to comprehensive care for cancer patients? A systematic literature review;Journal of Cancer Policy;2022-12

5. Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis;Therapeutic Advances in Medical Oncology;2019-01